The SEC filings page for Rapport Therapeutics, Inc. (Nasdaq: RAPP) provides access to the company’s official regulatory disclosures as a clinical-stage biotechnology issuer. Rapport’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on The Nasdaq Global Market under the symbol RAPP, so its filings offer detailed information on its precision neuroscience business and capital markets activity.
Through this page, readers can review Form 10-K and Form 10-Q reports (when filed) for discussions of Rapport’s RAP technology platform, the development of RAP-219 for drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain, and additional programs in chronic pain, migraine, and hearing or vestibular disorders. These periodic reports also describe risk factors, research and development expenses, and other elements of the company’s operating profile.
Frequent Form 8-K filings from RAPP document material events such as positive Phase 2a trial results for RAP-219 in focal onset seizures, new data analyses presented at scientific meetings, public offerings of common stock under an effective shelf registration statement on Form S-3, and quarterly financial results and business updates. Some 8-Ks also summarize regulatory developments, including clinical holds, end-of-Phase 2 planning, and changes to at-the-market sales arrangements.
Investors can also use this page to locate information related to shareholder meetings and voting outcomes, as disclosed in 8-K items covering submissions of matters to a vote of security holders. Insider transaction reports on Form 4, when available, complement these filings by showing equity activity by directors and officers.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings, highlight clinical and financial milestones, and make it easier to understand how new disclosures may relate to Rapport’s RAP-219 program and broader precision neuroscience pipeline. Real-time updates from EDGAR help ensure that new RAPP filings, including 10-K, 10-Q, 8-K, and Form 4 submissions, are quickly accessible in one place.
Rapport Therapeutics, Inc. (RAPP) Chief Executive Officer Abraham Ceesay sold 2,210 shares of common stock on October 21, 2026, at a weighted average price of $29.1618 per share. The shares were sold in multiple transactions ranging from $28.89 to $29.55 under a Rule 10b5-1 trading plan adopted March 27, 2026. After the sale, Ceesay held 450,035 shares directly. Reported indirect holdings included 81,729 shares by Ceesay Family Irrevocable Trust and 20,729 shares by Dorothy Ceesay Irrevocable Trust.
Rapport Therapeutics, Inc. director Ramiro Sanchez purchased 3,600 shares of common stock on October 23, 2026, at a weighted average price of $27.3549 per share. The shares were purchased in multiple transactions at prices ranging from $27.07 to $27.47, inclusive. His reported direct holdings after the purchase were 3,600 shares. No Rule 10b5-1 plan is reported.
Rapport Therapeutics, Inc. (RAPP) director Paul M. Silva reported a purchase through the Paul M Silva 2016 Declaration of Trust U/A DTD 12/19/2016. The trust purchased 3,680 shares for $27.0750 per share on October 22, 2026; the transaction is described as a purchase in the open market or a private transaction. The trust held 3,680 shares following the transaction, and no Rule 10b5-1 plan is reported.
Rapport Therapeutics, Inc. (RAPP) director Wendy B. Young purchased 3,789 shares of common stock on October 22, 2026, at $26.39 per share. The purchase was directly held, bringing her reported direct holdings to 13,289 shares. No Rule 10b5-1 plan is reported.
Rapport Therapeutics, Inc. director Steven M. Paul reported that Paul Capital Strategy III Fund LLC purchased 35,714 shares of common stock on October 22, 2026. The $27.28 per-share weighted average reflects multiple transactions priced from $26.87 to $27.84. After the purchase, the LLC held 77,380 shares. Paul disclaims beneficial ownership of those shares except to the extent of any pecuniary interest; the report also lists 477,642 shares held directly as of October 22, 2026. No Rule 10b5-1 plan is reported.
John Maraganore, a director of Rapport Therapeutics, reported that John M. Maraganore Revocable Trust purchased 9,411 shares of common stock on October 22, 2026, across two purchase groups. The trust bought 8,239 shares at a weighted average of $26.3799 per share, with prices ranging from $25.81 to $26.73, and 1,172 shares at a weighted average of $26.9173 per share, with prices ranging from $26.81 to $26.98.
Rapport Therapeutics, Inc. (RAPP) Chief Financial Officer Troy A. Ignelzi purchased 5,500 shares of Common Stock on October 21, 2026, at $26.10 per share. The shares were held directly, and his reported direct holdings after the purchase were 15,500 shares. No Rule 10b5-1 plan is reported for the purchase.
Rapport Therapeutics (RAPP) reported positive topline results from its Phase 2 trial of RAP-219 in adults with acute mania associated with bipolar I disorder. At Week 3, the Young Mania Rating Scale (YMRS) showed a 3.1-point placebo-adjusted improvement (p=0.045), with mean reductions from baseline of 15.4 points with RAP-219 and 12.3 points with placebo. The trial also met its secondary endpoint, with a 0.4-point placebo-adjusted improvement in CGI-BP Severity of Mania (p=0.024).
The randomized, double-blind trial enrolled 253 adults treated for three weeks in an inpatient setting. During treatment, all treatment-emergent adverse events were mild or moderate, and there were no severe TEAEs or serious adverse events. Treatment discontinuation occurred in 24.6% of the RAP-219 group and 11.8% of the placebo group. Safety data from the eight-week post-treatment period are planned for a future medical conference.
Rapport plans to meet with the FDA in the first quarter of 2027 to discuss the data and registrational trial design; initiation of two Phase 3 trials is expected in the second half of 2027.
Rapport Therapeutics, Inc. (RAPP) Chief Executive Officer Abraham Ceesay reported direct sales of 3,375 shares at a weighted average $32.0314 per share on October 6, 2026, and 1,147 shares at a weighted average $30.6600 per share on October 7, 2026. Both sales were made under Rule 10b5-1 trading plans adopted on March 27, 2026.
As of October 6, 2026, the Ceesay Family Irrevocable Trust held 81,729 shares indirectly, and the Dorothy Ceesay Irrevocable Trust held 20,729 shares indirectly.
Rapport Therapeutics, Inc. (RAPP) lists a proposed sale by its Officer, Abraham N. Ceesay, of 39,470 common shares, with an aggregate market value of $1,229,490.50. Goldman Sachs & Co. LLC is listed as the broker, and October 6, 2026, as the approximate sale date. The notice connects the sale to a selling plan dated March 27, 2026, intended to comply with Rule 10b5-1(c). It also lists prior sales by Ceesay during the preceding three months, including 22,541 shares on August 10, 2026, 28,958 shares on August 11, 2026, and 8,501 shares on August 25, 2026.